U-CH2

  1. Resources for researchers
  2. Disease models
  3. U-CH2

General Characteristics


Age:		 72 years

Gender:
 Female

Disease Origin:
 Sacral

Disease Status:
 Recurrent

Prior Radiation:
 No
Prior Systemic Therapy: No
Source: Silke Bruderlein, Peter Moller
University of Ulm

Molecular Features

Cell Morphology: Physaliferous
TBXT Expression: Positive; with T amplification
TBXT Localization: Nuclear
CD24 Expression: Positive
HLA Type: A11 (View Histocompatibility Report)
Sequence Data:

WGS, Exome and Transcriptome data available: raw sequencing data in Cavatica (Chordoma Foundation Dataset) and summary data in PedcBioportal. Contact researchteam@chordoma.org with any questions.
SMARCB1 Status: No expression
Validation Results: Validation Report

Growth Conditions

Growth Medium: IMDM: RPMI-1640 (4:1) +10% FBS
Freeze Medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing Instructions: Cell Culture Procedures

Publications

Characterized By:
  • Brüderlein S, Sommer J, Meltzer P, Li S, Osada T et al. (2010) Molecular Characterization of Putative Chordoma Cell Lines. Sarcoma: 630129. PubMed: 21253487.

Additional References:

  • Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M et al. Molecular profiling of chordoma. Int J Oncol 44(4):1041-55. PubMed: 24452533.
  • Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14(7):638-47. PubMed: 23792643.